N/A
Manufactured by Aurobindo Pharma Limited
6,348 FDA adverse event reports analyzed
Last updated: 2026-04-15
CEFADROXIL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for CEFADROXIL include PAIN, PNEUMONIA, DRUG HYPERSENSITIVITY, DYSPNOEA, VOMITING. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CEFADROXIL.
Out of 1,842 classified reports for CEFADROXIL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 6,348 FDA FAERS reports that mention CEFADROXIL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include PAIN, PNEUMONIA, DRUG HYPERSENSITIVITY, DYSPNOEA, VOMITING, ASTHMA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with CEFADROXIL. Always verify the specific product and NDC with your pharmacist.